This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Higa, G. M Articles by Abraham, J. Search for Related Content PubMed PubMed Citation Articles by Higa, G. M Articles by Abraham, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB FLUOROURACIL Social Bookmarking                         What's this?

Actinic keratosis and capecitabine therapy

Department of Medicine, Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA

Rodney F Kovach, MD

Department of Medicine, Section of Dermatology

Jame Abraham, MD

Department of Medicine, Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA

Topical application of 5-fluorouracil (5-FU) is one of the most effective clinical strategies available to treat actinic keratosis (AK). During treatment, an apparent toxic skin reaction occurs before dermal quiescence ensues. We report a case of a typical flare of AK in a woman treated with capecitabine for advanced breast cancer.

Key Words: actinic keratosis • capecitabine • 5-FU

Journal of Oncology Pharmacy Practice, Vol. 11, No. 4, 151-153 (2005)
DOI: 10.1191/1078155205jp163cr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?